Brooks Laboratories Limited has scheduled its 24th Annual General Meeting (AGM) for Thursday, September 3, 2026, marking a key governance event for shareholders of the pharmaceutical manufacturer. The meeting will commence at 9:00 a.m. IST and be conducted exclusively through Video Conferencing or Other Audio-Visual Means (VC/OAVM), aligning with regulatory mandates from the Securities and Exchange Board of India (SEBI) and the Ministry of Corporate Affairs (MCA). This virtual format ensures broader accessibility for stakeholders while adhering to the Companies Act, 2013.

The company notified stock exchanges on August 13, 2026, regarding the upcoming AGM, with advertisements published in Financial Express and Jansatta newspapers to ensure wide dissemination among investors. Pursuant to Section 91 of the Companies Act, the Register of Members will remain closed from Thursday, August 27, 2026, through Thursday, September 3, 2026, inclusive of both dates. This closure period is standard procedure to determine the final list of shareholders eligible to vote and receive dividends during the AGM.

Shareholders are required to register their email addresses with their Depository Participants (DPs) or the Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited, to receive the AGM notice and the Annual Report for Financial Year 2025-26 electronically. For those who have not registered email IDs, the company will dispatch a letter containing a web link to access these documents. Physical copies of the notice and annual report will be provided only upon specific request by members.

The company emphasizes that attendance via VC/OAVM counts toward the quorum requirement under Section 103 of the Companies Act. Detailed instructions for joining the virtual meeting and casting votes through the e-voting system—managed by CDSL—are included in the AGM notice. Shareholders holding physical shares or those without registered emails can still participate in remote e-voting by following the procedures outlined in the notice.

All relevant documents, including the AGM notice and the FY2025-26 Annual Report, will be available on the company’s website, www.brookslabs.net , as well as on the BSE and NSE platforms. This digital-first approach reflects the ongoing shift toward paperless corporate communications, aiming to enhance transparency and ease of access for all investors.

Key Dates and Details

What the Numbers Show

While no financial metrics were disclosed in this specific announcement, the scheduling of the AGM implies the finalization of audited results for FY2025-26. The reliance on electronic communication highlights the company's adherence to modern compliance standards, reducing physical paperwork and accelerating information delivery to shareholders.

Brooks Laboratories Ltd has appointed Mr. Rajesh Mahajan as President - Trading and Senior Management Personnel effective July 17, 2026. The appointment aims to leverage his extensive expertise in pharmaceutical formulations and manufacturing operations to drive the company's formulation business and new project initiatives.

The disclosure was made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company submitted the required details in compliance with SEBI Master Circular No. SEBIHO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Mr. Rajesh Mahajan holds a Bachelor's Degree in Biology and an MBA in Marketing. He possesses over 20 years of experience in the pharmaceutical industry, with a specific focus on formulations and manufacturing operations. His previous contributions include playing a key role in the growth of Brooks Laboratories 's formulation business and executing business development strategies.

The appointment details were formally communicated to BSE Limited and the National Stock Exchange of India Ltd. The information has been made available on the company's official website.

Key Appointment Details